Symbol="INZY"
AssetType="Common Stock"
Name="Inozyme PharmaÂ Inc"
Description="Inozyme Pharma, Inc., a rare disease biopharmaceutical company, is dedicated to developing therapies for the treatment of abnormal mineralization that impacts the vasculature, soft tissue, and skeletal diseases. The company is headquartered in Boston, Massachusetts."
CIK="1693011"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="321 SUMMER STREET, SUITE 400, BOSTON, MA, US"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="258928000"
EBITDA="-69432000"
PERatio="None"
PEGRatio="None"
BookValue="2.361"
DividendPerShare="0"
DividendYield="0"
EPS="-1.4"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.35"
ReturnOnEquityTTM="-0.684"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-1.4"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="20.83"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="0.381"
EVToRevenue="-"
EVToEBITDA="1.239"
Beta="0.998"
num_52WeekHigh="7.24"
num_52WeekLow="0.991"
num_50DayMovingAverage="5.96"
num_200DayMovingAverage="3.458"
SharesOutstanding="44035300"
DividendDate="None"
ExDividendDate="None"
symbol="INZY"
open="5.99"
high="6.40"
low="5.92"
price="6.30"
volume="713104.00"
latest_trading_day="2023-07-12"
previous_close="5.88"
change="0.42"
change_percent="7.1429%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="5"
trend_strength="Strong Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="95"
Volume_recent_avg="1326877"
Change_recent_avg="0.01"
Delta_recent_avg="0.45"
Variance_recent_avg="0.23"
Change_ratio_recent_avg="0.22"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="95"
Aroon_momentum_negative="5"
image_negative_thumbnail_id_1="1143"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0176.jpeg"
image_negative_thumbnail_id_2="1128"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0161.jpeg"
image_neutral_thumbnail_id_1="551"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0048.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="628"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0080.jpeg"
image_positive_thumbnail_id_2="674"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0034.jpeg"
image_professor_thumbnail_id_1="1183"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0017.jpeg"
image_professor_thumbnail_id_2="1203"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0037.jpeg"
